TG Therapeutics (TGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research • Monday
TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026Business Wire • 10/23/26
TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026Business Wire • 10/21/26
TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple SclerosisBusiness Wire • 10/12/26
TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire • 09/10/26
TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 09/02/26
TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical DetectionMarketBeat • 08/18/26
TGTX Q2 Earnings Lag, Sales Rise Y/Y, 2026 View Raised, Stock DownZacks Investment Research • 08/03/26
Here's What Key Metrics Tell Us About TG Therapeutics (TGTX) Q2 EarningsZacks Investment Research • 08/03/26
TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue GuidanceGlobeNewsWire • 08/03/26